Here's When Pfizer's CEO Says the Company Might Get Back to Generating High-Single-Digit GrowthThe Motley Fool • 06/15/26
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?Zacks Investment Research • 06/15/26
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry AboutThe Motley Fool • 06/12/26
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy24/7 Wall Street • 06/12/26
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It's a Flawless Safe-Haven for Retirees24/7 Wall Street • 06/11/26
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $2524/7 Wall Street • 06/11/26
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?The Motley Fool • 06/11/26
Roche Vs. Pfizer: Obesity Week Presentations Deep Dive - What Investors Must KnowSeeking Alpha • 06/10/26
The space race is coming for pharma: Why drug development is heading to lower Earth orbitCNBC • 06/09/26
Pfizer Inc. (PFE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeeking Alpha • 06/08/26
U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical NeedBusiness Wire • 06/08/26
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer.The Motley Fool • 06/06/26
Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It SeemsThe Motley Fool • 06/06/26
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trialReuters • 06/06/26